Disparities in the practice of precision medicine? Using multi-gene testing in early-stage, HR+/HER2-breast cancer

被引：0
|
作者：
Bilani, Nadeem
Yaghi, Marita
Saravia, Diana
Jabbal, Iktej
Zerdan, Maroun Bou
Elson, Leah
Hong, Liang
Nahleh, Zeina
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-08-33
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-08-33
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Everolimus and Exemestane An Innovative Therapeutic Option for Patients with advanced HR+, HER2-Breast Cancer
    Grischke, Eva-Maria
    Geberth, Matthias
    Harbeck, Nadia
    AKTUELLE NEUROLOGIE, 2014, 41 (08) : 4 - 6
  • [32] A phase 2 study of abemaciclib in patients with leptomeningeal metastases secondary to HR+, HER2-breast cancer
    Tolaney, S. M.
    Sahebjam, S.
    Le Rhun, E.
    Lin, Nu
    Bear, M. Markel
    Yang, Z.
    Chen, Y.
    Anders, C. K.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] Selection for Oncotype Dx testing among young women with early-stage ER+/HER2-breast cancer.
    Poorvu, Philip Daniel
    Gelber, Shari I.
    Rosenberg, Shoshana M.
    Ruddy, Kathryn Jean
    Tamimi, Rulla
    Peppercorn, Jeffrey M.
    Schapira, Lidia
    Borges, Virginia F.
    Come, Steven E.
    Collins, Laura C.
    Warner, Ellen
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] The use of Ki67 testing and scoring in HR+, HER2-early breast cancer
    Brown, J.
    Scardo, S.
    Method, M.
    Schlauch, D.
    Misch, A.
    Picard, S.
    Hamilton, E. P.
    Jones, S.
    Burris, H.
    Spigel, D. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S315 - S315
  • [35] Multiparametric prognostic score in early HR+/HER2-breast cancer: Impact of recurrence score, clinical-pathological factors, gene mutations and histology
    Gluz, O.
    Christgen, M.
    Eulenburg, C. Zu
    Nitz, U. A.
    Kummel, S.
    Braun, M.
    Aktas, B.
    Luedtke-Heckenkamp, K.
    Forstbauer, H.
    Grischke, E. M.
    Schumacher, C.
    Baehner, R. F. L.
    Kates, R. E.
    Graeser, M.
    Wurstlein, R.
    Kreipe, H.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S1262 - S1263
  • [36] The MAGIC survey in HR+, HER2-breast cancer (BC): when might multigene assays be of value?
    Aapro, M.
    De laurentiis, M.
    Linderholm, B.
    Mamounas, E.
    Markopoulos, C.
    Martin, M.
    Neven, P.
    Rea, D.
    Rouzier, R.
    Thomssen, C.
    BREAST, 2015, 24 : S61 - S61
  • [37] Controversial topics in metastatic HR+/HER2-breast cancer: Guiding treatment by a modified Delphi approach
    Fabi, Alessandra
    Buono, Giuseppe
    Bria, Emilio
    Bianchini, Giampaolo
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    De Placido, Sabino
    Del Mastro, Lucia
    Guarneri, Valentina
    Generali, Daniele
    Livi, Lorenzo
    Lorusso, Vito
    Montemurro, Filippo
    Puglisi, Fabio
    Vigneri, Paolo
    Zambelli, Alberto
    Arpino, Grazia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [38] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
  • [39] Advances in the mechanism of CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
    Wu, Sijia
    Xu, Junnan
    Ma, Yiwen
    Liang, Guilian
    Wang, Jiaxing
    Sun, Tao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [40] Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2-breast cancer
    Hurvitz, S.
    Martin, M.
    Fernandez Abad, M.
    Chan, D.
    Rostorfer, R.
    Petru, E.
    Barriga, S.
    Costigan, T. M.
    Caldwell, C. W.
    Nguyen, T.
    Press, M.
    Slamo, D.
    CANCER RESEARCH, 2017, 77
12345